These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 30753579)

  • 1. Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus.
    Schiff D; Van den Bent M; Vogelbaum MA; Wick W; Miller CR; Taphoorn M; Pope W; Brown PD; Platten M; Jalali R; Armstrong T; Wen PY
    Neuro Oncol; 2019 Jul; 21(7):837-853. PubMed ID: 30753579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.
    Miller JJ; Gonzalez Castro LN; McBrayer S; Weller M; Cloughesy T; Portnow J; Andronesi O; Barnholtz-Sloan JS; Baumert BG; Berger MS; Bi WL; Bindra R; Cahill DP; Chang SM; Costello JF; Horbinski C; Huang RY; Jenkins RB; Ligon KL; Mellinghoff IK; Nabors LB; Platten M; Reardon DA; Shi DD; Schiff D; Wick W; Yan H; von Deimling A; van den Bent M; Kaelin WG; Wen PY
    Neuro Oncol; 2023 Jan; 25(1):4-25. PubMed ID: 36239925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in
    Batchala PP; Muttikkal TJE; Donahue JH; Patrie JT; Schiff D; Fadul CE; Mrachek EK; Lopes MB; Jain R; Patel SH
    AJNR Am J Neuroradiol; 2019 Mar; 40(3):426-432. PubMed ID: 30705071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
    Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
    J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diffuse Infiltrating Oligodendroglioma and Astrocytoma.
    van den Bent MJ; Smits M; Kros JM; Chang SM
    J Clin Oncol; 2017 Jul; 35(21):2394-2401. PubMed ID: 28640702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.
    Chen R; Ravindra VM; Cohen AL; Jensen RL; Salzman KL; Prescot AP; Colman H
    Neurosurg Focus; 2015 Mar; 38(3):E2. PubMed ID: 25727224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.
    Miller JJ; Shih HA; Andronesi OC; Cahill DP
    Cancer; 2017 Dec; 123(23):4535-4546. PubMed ID: 28980701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.
    Etxaniz O; Carrato C; de Aguirre I; Queralt C; Muñoz A; Ramirez JL; Rosell R; Villà S; Diaz R; Estival A; Teixidor P; Indacochea A; Ahjal S; Vilà L; Balañá C
    J Neurooncol; 2017 Nov; 135(2):273-284. PubMed ID: 28884377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas.
    Yamauchi T; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Kitagawa Y; Kondo E; Tsushita N; Satomi K; Yoshida A; Ichimura K; Narita Y
    Brain Tumor Pathol; 2018 Jul; 35(3):148-158. PubMed ID: 29922974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome.
    Kiviniemi A; Gardberg M; Kivinen K; Posti JP; Vuorinen V; Sipilä J; Rahi M; Sankinen M; Minn H
    Oncotarget; 2017 Jul; 8(30):49123-49132. PubMed ID: 28467778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI and CT Identify Isocitrate Dehydrogenase
    Patel SH; Batchala PP; Mrachek EKS; Lopes MS; Schiff D; Fadul CE; Patrie JT; Jain R; Druzgal TJ; Williams ES
    Radiology; 2020 Jan; 294(1):160-167. PubMed ID: 31714193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extent of Surgical Resection in Lower-Grade Gliomas: Differential Impact Based on Molecular Subtype.
    Patel SH; Bansal AG; Young EB; Batchala PP; Patrie JT; Lopes MB; Jain R; Fadul CE; Schiff D
    AJNR Am J Neuroradiol; 2019 Jul; 40(7):1149-1155. PubMed ID: 31248860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of Isocitrate Dehydrogenase Genotype in Brain Gliomas with MRI: Single-Shell versus Multishell Diffusion Models.
    Figini M; Riva M; Graham M; Castelli GM; Fernandes B; Grimaldi M; Baselli G; Pessina F; Bello L; Zhang H; Bizzi A
    Radiology; 2018 Dec; 289(3):788-796. PubMed ID: 30277427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
    Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A
    Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What's New in Grade II and Grade III Gliomas?
    Miller JJ; Wick W
    Semin Neurol; 2018 Feb; 38(1):41-49. PubMed ID: 29548051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological tumour volumes of gliomas in early and standard 20-40 min
    Unterrainer M; Winkelmann I; Suchorska B; Giese A; Wenter V; Kreth FW; Herms J; Bartenstein P; Tonn JC; Albert NL
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1242-1249. PubMed ID: 29487977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.
    Malzkorn B; Reifenberger G
    Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuro-radiological characteristics of adult diffuse grade II and III insular gliomas classified according to WHO 2016.
    Compes P; Tabouret E; Etcheverry A; Colin C; Appay R; Cordier N; Mosser J; Chinot O; Delingette H; Girard N; Dufour H; Metellus P; Figarella-Branger D
    J Neurooncol; 2019 May; 142(3):511-520. PubMed ID: 30756272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
    Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
    Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.